Amit Kumar recently left his position as President and CEO of CombiMatrix Corporation (CBMX:NASDAQ), a position he has held since September 2001. CBMX is a biotech company that Dr. Kumar took public, and is focused on genetic analysis to enable personalized medical management for patients. He continues on the Board of Directors of CombiMatrix. He. also sits on the Boards of two other public companies Aeolus Pharmaceuticals, a small drug development company (AOLS:OTC), and Ascent Solar Technologies, a photovoltaics company (ASTI:NASDAQ), where he is the Chairman of the Board. He is also a cofounder and sits on the Board of Tacere Therapeutics (a private siRNA drug developer which he co-founded, that in partnership with Pfizer is developing a therapy for Hepatitis C) and is an advisor to other companies in the Cleantech/Energy and Life Science industries. Dr. Kumar is currently developing a number of new companies in the life sciences and energy fields.. Before, CombiMatrix, he was VP Life Sciences for Acacia Research Corporation (ACTG:NASDAQ), a publicly traded venture capital firm. Previous to that he was the founding CEO of Signature BioSciences, a drug discovery company. Prior to Signature, Dr. Kumar was engaged as an Entrepreneur-in-Residence for Oak Investment Partners, a venture capital firm. Previous to Oak, Dr. Kumar was Senior Manager for Futures Technology and General Manager for IDEXX (NASDAQ:IDXX) Laboratories’ west coast R&D operations. Prior to IDEXX, Dr. Kumar was Program Manager for New Technology at Idetek, Dr. Kumar has also been an advisor or consultant to Fortune 500 companies, venture capital firms, and private early stage healthcare companies. He has over 60 peer-reviewed technical publications and holds over a dozen patents with several others pending.. Dr. Kumar also has extensive experience working with the US government, having presented to members of the House and Senate as well as major defense organizations.
